Company news

Oncolytics Biotech Inc. news in 2025

Oncolytics Biotech Inc.'s news releases, calls and decks from 2025, newest first.

View company

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

December 15, 2025

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

December 8, 2025

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

November 19, 2025

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

November 18, 2025

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

November 3, 2025

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

October 28, 2025

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

October 19, 2025

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

September 28, 2025

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

September 15, 2025

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

September 7, 2025

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

September 1, 2025

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

August 28, 2025

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

August 26, 2025

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

August 14, 2025

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

August 14, 2025

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

August 11, 2025

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

August 8, 2025

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

August 8, 2025

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

August 5, 2025

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

July 29, 2025

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

July 29, 2025

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

July 23, 2025

High?Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

July 23, 2025

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

July 22, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

July 16, 2025

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

July 16, 2025

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

July 10, 2025

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

July 10, 2025

Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

July 8, 2025

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

July 8, 2025

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

June 30, 2025

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

June 30, 2025

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

June 26, 2025

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

June 24, 2025

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

June 20, 2025

Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

June 18, 2025

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

June 12, 2025

After Major Oncology Conference, All Eyes Turn to Industry Innovation

June 12, 2025

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

June 11, 2025

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

May 23, 2025

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 14, 2025

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6, 2025

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

May 1, 2025

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

April 24, 2025

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

April 10, 2025

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

April 10, 2025

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

March 8, 2025

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

March 7, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

February 27, 2025

Older news releases →

Calls in 2025

Decks in 2025